



# EHA2026 Congress

June 11–14, 2026  
Stockholm, Sweden



## TOP ABSTRACTS

To help navigate the exciting content being presented at the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the ALL Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in ALL.

Thank you to the funders of the ALL Hub. All content is developed independently by SES in collaboration with an expert steering committee. Funders are allowed no influence. A full list of our current funders can be found at: [Lymphoblastic-Hub.com](https://lymphoblastic-hub.com).

# EHA2026: Top abstracts in ALL

June 11–14, 2026

## Oral presentations: Thursday, June 11

Abstract	Title	Presenter	Time (CEST)
<b>S135</b> <a href="#">View</a>	Tisagenlecleucel in pediatric and young adult patients with high-risk B-cell acute lymphoblastic leukemia and minimal residual disease at the end of frontline consolidation	Shannon Maude	16:45–17:00

## Oral presentations: Thursday, June 11

Abstract	Title	Presenter	Time (CEST)
<b>S103</b> <a href="#">View</a>	Replacement of high dose combination chemotherapy with blinatumomab in newly diagnosed pediatric high-risk B-cell ALL improves efficacy and safety in the randomized phase 3 AIEOP-BFM ALL 2017 trial	Martin Schrappe	13:00–13:15
<b>S110</b> <a href="#">View</a>	Long-term outcomes of naturally selected CD7 CAR-T therapy in relapsed/refractory T-lymphoblastic leukemia/lymphoma: A cohort of 171 patients	Xian Zhang	17:15–17:30
<b>S111</b> <a href="#">View</a>	Antibody-based immunotherapy versus cellular therapy as bridging to allogeneic stem cell transplantation in relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia	Ao-ran Zhang	17:30–17:45
<b>S112</b> <a href="#">View</a>	Comparison of end induction flow cytometry versus high-throughput sequencing based minimal residual disease in newly diagnosed childhood standard risk B ALL: A report from COG AALL1731	Sumit Gupta	17:45–18:00
<b>S113</b> <a href="#">View</a>	Improving efficacy and safety outcomes in patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia in morphologic remission treated with obecabtagene autoleucel (obe-cel)	Claire Roddie	18:00–18:15
<b>S114</b> <a href="#">View</a>	Safety and efficacy of UCART22 in heavily pre-treated patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia (B-ALL): Results of the phase 1 BALLI-01 trial	Nitin Jain	18:15–18:30

## Posters

Abstract	Title	Presenter	Date and time (CEST)
<b>PF375</b> <a href="#">View</a>	Frontline CD19-directed CAR T-cell therapy as consolidation in high-risk B-ALL: A real-world single-center experience	Thomase Eipe	Friday, June 12, from 18:45
<b>PF376</b> <a href="#">View</a>	Early use of inotuzumab ozogamicin in first remission achieves deep and durable MRD eradication in adults with Philadelphia chromosome-negative B-ALL: A prospective phase II study	Runxia Gu	Friday, June 12, from 18:45

## Posters (continued)

Abstract	Title	Presenter	Date and time (CEST)
<b>PF386</b> <a href="#">View</a>	Venetoclax, cladribine, and low-dose cytarabine for the treatment of Ph- relapse/refractory acute lymphoblastic leukemia: An analysis of a phase 2 trial	Shengli Xue	Friday, June 12, from 18:45
<b>PF390</b> <a href="#">View</a>	Chemotherapy-free regimen following PhALLCON cytoreduction in adults with newly diagnosed Philadelphia positive acute lymphoblastic leukemia	Ibrahim Aldoss	Friday, June 12, from 18:45
<b>PF404</b> <a href="#">View</a>	Asciminib effectiveness in patients with Philadelphia [HC1.1]chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in the real world: The ASCERTAIN study	Marlise Luskin	Friday, June 12, from 18:45
<b>PF405</b> <a href="#">View</a>	Real-world incidence and management of CRS and ICANS in adults with newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia treated with frontline TKI plus blinatumomab	Rosa Ancaya	Friday, June 12, from 18:45
<b>PS1478</b> <a href="#">View</a>	A phase II study of venetoclax plus mini-hyper-CVD in older adults with <i>de novo</i> Philadelphia negative ALL	Marlise Luskin	Saturday, June 13, from 18:45
<b>PS1481</b> <a href="#">View</a>	Subcutaneous blinatumomab for patients with relapsed/refractory Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: Results from a phase 1/2 study	Elias Jabbour	Saturday, June 13, from 18:45
<b>PS1484</b> <a href="#">View</a>	The effect of obecabtagene autoleucel on adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia and extramedullary disease	Jae H. Park	Saturday, June 13, from 18:45
<b>PS1485</b> <a href="#">View</a>	Combination therapy with blinatumomab and asciminib for Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from a phase I/II study	Nicholas Short	Saturday, June 13, from 18:45
<b>PS1489</b> <a href="#">View</a>	Phase II study of dose-adjusted epoch ± rituximab (R) + tafasitamab (Tafa) in newly-diagnosed (ND) adults with Philadelphia chromosome negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL)	Ryan Cassaday	Saturday, June 13, from 18:45
<b>PS2350</b> <a href="#">View</a>	TENACITY-01 a global study of CTD402, allogeneic anti-CD7 CAR T-cell, in relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL)	Lori Muffly	Saturday, June 13, from 18:45



**#EHA2026**

Follow us on X to keep up to date  
with the latest from the congress

**@ALL\_Hub\_**



Brought to you by

